Retroperitoneal Ligation of Uterine Artery in Total Laparoscopic Hysterectomy for Enlarged Uterus
Launched by KANGBUK SAMSUNG HOSPITAL · Apr 3, 2017
Trial Information
Current as of May 15, 2025
Suspended
Keywords
ClinConnect Summary
Laparoscopic hysterectomy is one of the most common gynecologic surgeries worldwide. Generally, in total laparoscopic hysterectomy (TLH), uterine arteries are coagulated or transected close to the uterus, alongside the cervix, like surgical technique of a conventional total abdominal hysterectomy. Recently, several studies showed that ligation of uterine artery where it originates from the internal iliac artery during TLH (so-called "retroperitoneal TLH") is effective for reducing blood loss. However, the application of this technique to clinical practice have not been well investigated in ...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • absence of pregnancy at the time of presentation
- • uterine volume between 12 and 18 weeks of gestation by pelvic examination
- • appropriate medical status for laparoscopic surgery (American Society of Anesthesiologists Physical Status classification 1 or 2)
- Exclusion Criteria:
- • any suggestion of malignant uterine or adnexal diseases
- • any major medical comorbidities or psychiatric illnesses, which could affect follow-up and/or compliance
- • an inability to understand and provide written informed consent.
About Kangbuk Samsung Hospital
Kangbuk Samsung Hospital is a leading healthcare institution in South Korea, renowned for its commitment to advanced medical research and clinical excellence. As a sponsor of clinical trials, the hospital integrates cutting-edge technology and innovative therapies to enhance patient care and outcomes. With a multidisciplinary team of experienced researchers and healthcare professionals, Kangbuk Samsung Hospital is dedicated to conducting rigorous clinical studies that adhere to the highest ethical standards. Its focus on translational medicine aims to bridge the gap between laboratory findings and clinical applications, ultimately contributing to the advancement of medical science and improving therapeutic options for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Taejong Song, MD PhD
Study Chair
Kangbuk Samsung Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials